Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888 · see citing works

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · see citing works

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611 · see citing works

DrugBank 5.0: a major update to the DrugBank database for 2018

Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · see citing works

In situ click chemistry generation of cyclooxygenase-2 inhibitors

Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448 · see citing works

An automated method for finding molecular complexes in large protein interaction networks

Bader, G. D., & Hogue, C. W. V. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-2 · Cited by 6,112 · see citing works

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515 · see citing works

GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists

Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation

Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works

MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes

McAlister, G. C., Nusinow, D. P., Jedrychowski, M. P., Wühr, M., Huttlin, E. L., Erickson, B. K., Rad, R., Haas, W., & Gygi, S. P. (2014) · Analytical Chemistry · doi:10.1021/ac502040v · Cited by 1,263 · see citing works

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion

Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang, L., Kremer, D., Hwang, R. F., Witkiewicz, A. K., Ying, H., et al. (2016) · Nature · doi:10.1038/nature19084 · Cited by 1,122 · see citing works

Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding

Tripathi, S., Pohl, M. O., Zhou, Y., Rodríguez-Frandsen, A., Wang, G., Stein, D. A., Moulton, H. M., DeJesus, P., Che, J., Mulder, L. C. F., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.11.002 · Cited by 846 · see citing works

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

IMAMURA, Y., MUKOHARA, T., SHIMONO, Y., FUNAKOSHI, Y., CHAYAHARA, N., TOYODA, M., KIYOTA, N., TAKAO, S., KONO, S., NAKATSURA, T., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3767 · Cited by 845 · see citing works

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · see citing works

<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710 · see citing works

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

KRAS: feeding pancreatic cancer proliferation

Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675 · see citing works

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · see citing works

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · see citing works

Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Piotrowska, Z., Niederst, M. J., Karlovich, C., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M. A., Fulton, L. E., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 459 · see citing works

Drugging an undruggable pocket on KRAS

Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449 · see citing works

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · see citing works

Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels

Mertins, P., Yang, F., Liu, T., Mani, D. R., Petyuk, V., Gillette, M. A., Clauser, K. R., Qiao, J., Gritsenko, M. A., Moore, R. J., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036392 · Cited by 407 · see citing works

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing

Longati, P., Jia, X., Eimer, J., Wagman, A., Witt, M.-R., Rehnmark, S., Verbeke, C., Toftgård, R., Löhr, M., & Heuchel, R. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-95 · Cited by 394 · see citing works

Comparison of cancer cells cultured in 2D vs 3D reveals differences in AKT/mTOR/S6-kinase signaling and drug response

Riedl, A., Schlederer, M., Pudelko, K., Stadler, M., Walter, S., Unterleuthner, D., Unger, C., Kramer, N., Hengstschläger, M., Kenner, L., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.188102 · Cited by 389 · see citing works

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369 · see citing works

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · see citing works

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R., Rabinovich, B. A., Hann, B. C., Dankort, D. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320 · see citing works

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320 · see citing works

Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism

Biancur, D. E., Paulo, J. A., Małachowska, B., Quiles Del Rey, M., Sousa, C. M., Wang, X., Sohn, A. S. W., Chu, G. C., Gygi, S. P., Harper, J. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15965 · Cited by 315 · see citing works

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance

Breslin, S., & O’Driscoll, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9935 · Cited by 312 · see citing works

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266 · see citing works

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259 · see citing works

A Convergence-Based Framework for Cancer Drug Resistance

Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258 · see citing works

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis

Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07472-8 · Cited by 252 · see citing works

Metabolic Dependencies in RAS -Driven Cancers

Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 220 · see citing works

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · see citing works

Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities

Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199 · see citing works

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Will, M., Qin, A. C. R., Toy, W., Yao, Z., Rodrik-Outmezguine, V. S., Schneider, C., Huang, X., Monian, P., Jiang, X., de Stanchina, E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0611 · Cited by 195 · see citing works

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 181 · see citing works

Survival of pancreatic cancer cells lacking KRAS function

Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · see citing works

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martínez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D. M., Sayles, L. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14294 · Cited by 175 · see citing works

KRAS ^G12C inhibition produces a driver-limited state revealing collateral dependencies

Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175 · see citing works

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <i>KRAS^G12C</i> inhibitor, in advanced solid tumors.

Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3003 · Cited by 172 · see citing works

Evaluating Multiplexed Quantitative Phosphopeptide Analysis on a Hybrid Quadrupole Mass Filter/Linear Ion Trap/Orbitrap Mass Spectrometer

Erickson, B. K., Jedrychowski, M. P., McAlister, G. C., Everley, R. A., Kunz, R. C., & Gygi, S. P. (2014) · Analytical Chemistry · doi:10.1021/ac503934f · Cited by 159 · see citing works

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in <i>KRAS</i> -Mutant Lung Cancer

Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · see citing works

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

Alagesan, B., Contino, G., Guimarães, A. R., Corcoran, R. B., Deshpande, V., Wojtkiewicz, G. R., Hezel, A. F., Wong, K., Loda, M. F., Weissleder, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1591 · Cited by 145 · see citing works

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136 · see citing works

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131 · see citing works

Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells

Yi, T., Zhai, B., Yu, Y., Yoshikawa, K., Raschle, T., Etzkorn, M., Seo, H., Nagiec, M. J., Luna, R. E., Reinherz, E. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404943111 · Cited by 124 · see citing works

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J. G., Jiang, R. H. Y., Ayaz, M., Lawrence, H. R., Kennedy, P., & Sebti, S. M. (2018) · Nature Communications · doi:10.1038/s41467-018-07644-6 · Cited by 122 · see citing works

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

Kim, J., Welsh, E. A., Oguz, U., Fang, B., Bai, Y., Kinose, F., Bronk, C. C., Rix, L. L. R., Beg, A. A., Rix, U., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220674110 · Cited by 120 · see citing works

Connexin-43-dependent ATP release mediates macrophage activation during sepsis

Dosch, M., Zindel, J., Jebbawi, F., Mélin, N., Sánchez‐Taltavull, D., Stroka, D., Candinas, D., & Beldi, G. (2019) · eLife · doi:10.7554/elife.42670 · Cited by 110 · see citing works

A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*

Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047233 · Cited by 106 · see citing works

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors

Schweppe, D. K., Rigas, J. R., & Gerber, S. A. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.07.023 · Cited by 99 · see citing works

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Acquaviva, J., Smith, D. L., Sang, J., Friedland, J. C., He, S., Sequeira, M., Zhang, C., Wada, Y., & Proia, D. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0615 · Cited by 96 · see citing works

Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors

Seth, S., Li, C.-Y., Ho, I.-L., Corti, D., Loponte, S., Sapio, L., Poggetto, E. D., Yen, E.-Y., Robinson, F. S., Peoples, M. D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.048 · Cited by 85 · see citing works

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 80 · see citing works

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS -Mutant Lung Cancer

Kim, J., Welsh, E. A., Fang, B., Bai, Y., Kinose, F., Eschrich, S. A., Koomen, J. M., & Haura, E. B. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0506 · Cited by 76 · see citing works

Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets

Britton, D., Zen, Y., Quaglia, A., Selzer, S., Mitra, V., Lößner, C., Jung, S., Böhm, G., Schmid, P., Prefot, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090948 · Cited by 59 · see citing works

Global Analysis of Protein Expression and Phosphorylation Levels in Nicotine-Treated Pancreatic Stellate Cells

Paulo, J. A., Gaun, A., & Gygi, S. P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00398 · Cited by 58 · see citing works

Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions

Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., & McCormick, F. P. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1623 · Cited by 54 · see citing works

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes

El‐Jawhari, J. J., El-Sherbiny, Y. M., Scott, G. B., Morgan, R. S. M., Prestwich, R. J. D., Bowles, P. A., Blair, G. E., Tanaka, T. U., Rabbitts, T. H., Meade, J. L., et al. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.020 · Cited by 54 · see citing works

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition

Dietrich, P., Kuphal, S., Spruß, T., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncogene · doi:10.1038/onc.2017.391 · Cited by 54 · see citing works

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway inKRAS-mutant non-small cell lung cancer

Haines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K., & Shapiro, G. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25803 · Cited by 53 · see citing works

Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells

Chen, P., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A. J., Rosario, A. M. D., Mertins, P., Qiao, J., Schäfer, C., Gertler, F. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 45 · see citing works

Organotypic three-dimensional cancer cell cultures mirror drug responses<i>in vivo</i>: lessons learned from the inhibition of EGFR signaling

Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43 · see citing works

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells

Ischenko, I., Petrenko, O., & Hayman, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4538 · Cited by 42 · see citing works

Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model

Gagliano, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i18.4466 · Cited by 37 · see citing works

Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity

Rao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34 · see citing works

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations

Fritsche‐Guenther, R., Zasada, C., Mastrobuoni, G., Royla, N., Rainer, R. J., Roßner, F., Pietzke, M., Klipp, E., Sers, C., & Kempa, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-27394-1 · Cited by 31 · see citing works

Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma

Sahu, N., Chan, E., Chu, F., Pham, T. Q., Koeppen, H., Forrest, W. F., Merchant, M. A., & Settleman, J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0009 · Cited by 30 · see citing works

Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas

Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Yamada, G., Hasegawa, T., Miyagi, Y., Niki, T., Watanabe, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4365 · Cited by 20 · see citing works

Proteome-Wide Protein Expression Profiling Across Five Pancreatic Cell Lines

Paulo, J. A., Mancias, J. D., & Gygi, S. P. (2017) · Pancreas · doi:10.1097/mpa.0000000000000800 · Cited by 19 · see citing works

Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy

Werner, K., Lademann, F., Thepkaysone, M.-L., Jahnke, B., Aust, D. E., Kahlert, C., Weber, G. F., Weitz, J., Grützmann, R., & Pilarsky, C. P. (2015) · Oncotarget · doi:10.18632/oncotarget.6766 · Cited by 15 · see citing works

MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells

Zhang, T., Li, Y., Zhu, Z., Gu, M., Newman, B. W., & Sun, D. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900321a · Cited by 13 · see citing works

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · see citing works

Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer

Aubert, L., Nandagopal, N., Steinhart, Z., Lavoie, G., Nourreddine, S., Berman, J. M., Saba-El-Leil, M. K., Papadopoli, D. J., Lin, S., Hart, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17549-y · Cited by 288 · see citing works

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264 · see citing works

The KRAS-G12C inhibitor: activity and resistance

Liu, J., Kang, R., & Tang, D. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 222 · see citing works

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Bartolacci, C., Andreani, C., do Vale, G. D., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G. W., Hodges, K. B., Starrett, J. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31963-4 · Cited by 179 · see citing works

NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins

Santana-Codina, N., del Rey, M. Q., Kapner, K. S., Zhang, H., Gikandi, A., Malcolm, C., Poupault, C. L., Kuljanin, M., John, K. M., Biancur, D. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0043 · Cited by 179 · see citing works

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

Song, H., Liu, D., Dong, S., Zeng, L., Wu, Z., Zhao, P., Zhang, L., Chen, Z., & Zou, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00300-w · Cited by 138 · see citing works

Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer

Ravichandran, M., Hu, J., Cai, C., Ward, N. P., Venida, A., Foakes, C., Kuljanin, M., Yang, A., Hennessey, C. J., Yang, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0044 · Cited by 80 · see citing works

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works

Drugging the Undruggable: Advances on RAS Targeting in Cancer

Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 73 · see citing works

Insights into protein post-translational modification landscapes of individual human cells by trapped ion mobility time-of-flight mass spectrometry

Orsburn, B. C., Yuan, Y., & Bumpus, N. N. (2022) · Nature Communications · doi:10.1038/s41467-022-34919-w · Cited by 71 · see citing works

Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer

Mukhopadhyay, S., Encarnación-Rosado, J., Lin, E. Y., Sohn, A. S. W., Zhang, H., Mancias, J. D., & Kimmelman, A. C. (2023) · Science Advances · doi:10.1126/sciadv.adf9284 · Cited by 65 · see citing works

Resistance looms for KRAS G12C inhibitors and rational tackling strategies

Zhang, J., Zhang, J., Liu, Q., Fan, X., Leung, E. L., Yao, X., & Liu, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108050 · Cited by 56 · see citing works

A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors

Weller, C. E., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B. J., Seamon, K. J., et al. (2025) · Science · doi:10.1126/science.ads0239 · Cited by 63 · see citing works

Thinking Differently about Cancer Treatment Regimens

Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 48 · see citing works

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

de Jesus, V. H. F., Mathias-Machado, M. C., de Farias, J. P. F., Aruquipa, M. P. S., Jacome, A. A. D. A., & Peixoto, R. D. (2023) · Cancers · doi:10.3390/cancers15205015 · Cited by 47 · see citing works

More to the RAS Story: KRAS ^G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS ^G12C

Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44 · see citing works

Targeting KRAS G12C with Covalent Inhibitors

Ostrem, J. M. L., & Shokat, K. M. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041621-012549 · Cited by 43 · see citing works

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

Ji, J., Wang, C., & Fakih, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s340392 · Cited by 39 · see citing works

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade

Anastasiou, P., Moore, C., Rana, S., Tomaschko, M., Pillsbury, C. E., de Castro, A., Boumelha, J., Mugarza, E., Trécesson, S. D. C., Mikolajczak, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52324-3 · Cited by 35 · see citing works

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer

Diehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 29 · see citing works

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach

McFall, T. B., & Stites, E. C. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110096 · Cited by 29 · see citing works

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 25 · see citing works

Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt

Tanaka, N., & Ebi, H. (2024) · Cancer Science · doi:10.1111/cas.16441 · Cited by 26 · see citing works

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Groendyke, B. J., Nabet, B., Mohardt, M. L., Zhang, H., Peng, K., Koide, E., Coffey, C. R., Che, J., Scott, D. A., Bass, A. J., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00338 · Cited by 24 · see citing works

Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg

Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 22 · see citing works

Bioinformatic Analysis of Temporal and Spatial Proteome Alternations During Infections

Rahmatbakhsh, M., Gagarinova, A. G., & Babu, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.667936 · Cited by 21 · see citing works

Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications

Yang, F., Xu, X.-L., Hu, T., Liu, J., Zhou, J.-Z., Ma, L., & Liu, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01527 · Cited by 21 · see citing works

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Macaya, I., Román, M., Welch, C., Entrialgo‐Cadierno, R., Salmón, M., Santos, A., Feliu, I., Kovalski, J. R., López, I., Rodríguez‐Remírez, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41828-z · Cited by 21 · see citing works

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 22 · see citing works

Inhibition of RAS: proven and potential vulnerabilities

Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 20 · see citing works

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS G12D Inhibitor MRTX1133

Orsburn, B. C. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00212 · Cited by 18 · see citing works

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

Zhang, H., Santana-Codina, N., Yu, Q., Poupault, C. L., Campos, C., Qin, X., Sindoni, N., Ciscar, M., Padhye, A., Kuljanin, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61242-x · Cited by 19 · see citing works

Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity

Koide, E., Mohardt, M. L., Doctor, Z. M., Yang, A., Hao, M., Donovan, K. A., Kuismi, C. C., Nelson, A. J., Abell, K., Aguiar, M., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300141 · Cited by 18 · see citing works

Conquering oncogenic KRAS and its bypass mechanisms

Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 17 · see citing works

KRASG12C inhibitor: combing for combination

Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 14 · see citing works

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients

Aran, V., Zalis, M. G., Montella, T. C., de Sousa, C. A. M., Ferrari, B. L., & Ferreira, C. G. (2021) · Medicina · doi:10.3390/medicina57101039 · Cited by 13 · see citing works

Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment

Han, Z., Zhou, D., Wang, J., Jiang, B., & Liu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188677 · Cited by 13 · see citing works

Single-cell sensor analyses reveal signaling programs enabling Ras-G12C drug resistance

Zhang, J. Z., Ong, S., Baker, D. A., & Maly, D. J. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01684-4 · Cited by 12 · see citing works

Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., Colantonio, S., & Blonder, J. (2021) · Oncotarget · doi:10.18632/oncotarget.28072 · Cited by 11 · see citing works

Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain

DeLiberty, J. M., Robb, R. N., Gates, C. E., & Bryant, K. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.010 · Cited by 9 · see citing works

AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues

Ma, T. P., Izrael-Tomasevic, A., Mroue, R. M., Budayeva, H. G., Malhotra, S., Raisner, R. M., Evangelista, M., Rose, C. M., Kirkpatrick, D. S., & Yu, K. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00703 · Cited by 10 · see citing works

Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells

Giorgio, E. D., Choudhary, H., Ferino, A., Cortolezzis, Y., Dalla, E., D’Este, F., Comelli, M., Rapozzi, V., & Xodo, L. E. (2023) · iScience · doi:10.1016/j.isci.2023.108566 · Cited by 10 · see citing works

ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC

Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Schiavon, C. R., Rebollo, E., Zhou, H., Huang, C., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01978-1 · Cited by 12 · see citing works

KRAS-targeted therapies in cancer: novel approaches and overcoming resistance

Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 10 · see citing works

The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations

Yu, J. X., Suh, J. M., Popova, K. D., Garcia, K., Joshi, T. V., Culbertson, B., Spinelli, J. B., Subramanyam, V., Lou, K., Charbonneau, T., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01130-5 · Cited by 8 · see citing works

Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications

Wang, X., Ni, R., Wang, X., & Li, X. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02559-5 · Cited by 9 · see citing works

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics

Hamilton, G., & Plangger, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1965123 · Cited by 7 · see citing works

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6 · see citing works

SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities

Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7 · see citing works

Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite

Perez, M., Bak, D. W., Bergholtz, S. E., Crooks, D. R., Arimilli, B. S., Yang, Y., Weerapana, E., Linehan, W. M., & Meier, J. L. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.014993 · Cited by 6 · see citing works

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M., & Prior, I. A. (2022) · Biochemical Journal · doi:10.1042/bcj20220440 · Cited by 6 · see citing works

Understanding and drugging RAS: 40 years to break the tip of the iceberg

Brady, D. C., Hmeljak, J., & Dar, A. C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049519 · Cited by 5 · see citing works

Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and future prospects

Miao, J., Guan, W., Wang, J., Gong, H., Xie, Q., & Gao, Y. (2026) · Hereditas · doi:10.1186/s41065-025-00570-w · Cited by 4 · see citing works

KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer

Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 5 · see citing works

Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives

Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 3 · see citing works

ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDACPreprint

Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Zhou, H., Huang, C., Scott, D. A., Bang, A. G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.19.594824 · Cited by 3 · see citing works

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells

Aguilar‐Valdés, A., González‐Vela, F., Sánchez‐Vidal, H., & Martínez‐Aguilar, J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300041 · Cited by 2 · see citing works

Synthetic and Medicinal Chemistry Perspectives on Cereblon‐Binding Molecular Glue Degraders: Recent Advances and Emerging Trends

Won, H.-J., Baek, S. M., Lee, M. H., Park, J. H., Shin, J., Yang, Y., Jang, Y. H., Inn, K., & Kim, N. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501208 · Cited by 1 · see citing works

On the Diophantine Equation 3 x + b3 y = 6 z

Sándor, J. (2001) · Octogon Mathematical Magazine archive · Cited by 1 · see citing works

Comparative Microsomal Proteomics of A Model Lung Cancer Cell Line NCI-H23 Reveals Distinct Differences Between Molecular Profiles of 3D and 2D Cultured CellsPreprint

Blonder, J., Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., & Colantonio, S. (2020) · Research Square · doi:10.21203/rs.3.rs-72194/v1 · Cited by 1 · see citing works

Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancerPreprint

Diehl, J. N., Klomp, J. E., Snare, K. R., Blake, D. R., Hibshman, P. S., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.27.441678

Aliquoting of isobaric labeling reagents for low concentration and single cell proteomics samplesPreprint

Yuan, Y., & Orsburn, B. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449560

Improving cancer therapy through unconventional strategies

Neto, J. M. F. (2021) · doi:10.33540/1009

Recent Developments, Challenges and Opportunities in Targeting the KRAS Pathway

Pothuganti, M. K., Mitra, S., Iyer, P. S., & Gowda, N. M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220704104028

Supplementary Data from NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins

Santana-Codina, N., del Rey, M. Q., Kapner, K. S., Zhang, H., Gikandi, A., Malcolm, C., Poupault, C. L., Kuljanin, M., John, K. M., Biancur, D. E., et al. (2023) · doi:10.1158/2159-8290.22541117.v1

Supplementary Data from NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins

Santana-Codina, N., del Rey, M. Q., Kapner, K. S., Zhang, H., Gikandi, A., Malcolm, C., Poupault, C. L., Kuljanin, M., John, K. M., Biancur, D. E., et al. (2023) · doi:10.1158/2159-8290.22541117

Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersPreprint

Takeda, M., Theardy, M. S., Sorokin, A. V., Coker, O., Marie, P. K., Chen, S., Yang, Z., Nguyen, P. T.-M., Wei, Y., Yao, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.06.606865

Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 InhibitionPreprint

Zhang, T., Shin, S., McCrimmon, C., Theocharous, M., Schittenhelm, R. B., Jardé, T., Daly, R. J., & Nguyen, L. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.27.620536

Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapiesPreprint

Vicent, S., Welch, C., Novoa, G., Vasquez-Valencia, C., Macaya, I., Jimenez-Alonso, J. J., Subrizio, A., Lagos, A. F., Llorente, S., Jimenez, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9085811/v1

What Are the Practical Applications of Single-Cell Proteomics?

Orsburn, B. C. (2026) · Proteomes · doi:10.3390/proteomes14020026

Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer

Shrivastava, A., Pederson, E. N., Nguyen, T. U., Chuen, J., Mohan, P., Pande, S., Toribio, A. R., Lecomte, N., Melchor, J. P., McAuliffe, J. C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117520

GALE-dependent glycoproteome remodelling is a determinant of oncogenic RAS transformationPreprint

Stölting, F., Vesce, R., Rodríguez-Santana, C., Ciscar, M., Delaidelli, A., Lin, Q., Ballmeyer, C., Chan, S., Lesch, R., Li, R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732364

Submicromolar imaging of intrinsic chromophores by two-photon photothermal microscopy captures mitochondrial response to chemotherapy

Hai, N., Dessai, C. V. P., Sun, D., Ao, J., Lyu, P., Zhu, Y., & Cheng, J. (2026) · Science Advances · doi:10.1126/sciadv.aee7678

Harnessing autophagy and its transcriptional regulation in tumorigenesis and neurodegeneration: Potential and existing therapeutic strategies

Suri, P., Daartey, A. B., Khan, D. M. I. O., Rayana, N. P., Chilamakuri, R., Godugu, D., Azad, M. G., Reeb, K. L., & Richardson, D. R. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100158

KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancerPreprint

DeLiberty, J. M., Kong, F. Y., Yu, Q., Sindoni, N., Lin, J., Kang, K., Kim, E. Y., Chen, S., Padhye, A., Coker, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756025

BindingDB Entry 50019670: Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications.

BindingDB (2024) · UC San Diego · doi:10.7270/q24t6prj

BindingDB Entry 50011650: Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.

BindingDB (2022) · UC San Diego · doi:10.7270/q2dj5k8c

Abstract C48: Defining mechanisms of adaptation to KRAS G12C inhibitors: Using quantitative proteomics to design combinatorial strategies in pancreatic cancer

Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Jedrychowski, M. P., Gikandi, A., Stańczak, M., Scott, D. A., Fendler, W. M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.panca19-c48

Abstract C024: Quantitative mass spectrometry-based multi-omic profiling to overcome drug resistance in pancreatic cancer post KRAS G12D inhibition

Yu, Q., Sindoni, N., Zhang, H., Li, Z., Paulo, J. A., Aguirre, A. J., & Mancias, J. D. (2024) · Cancer Research · doi:10.1158/1538-7445.pancreatic24-c024

Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling

Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adt6552 · Cited by 8 · see citing works

KRAS G12C Inhibition Remodels the Non-Small Cell Lung Cancer Surfaceome to Uncover Targetable VulnerabilitiesPreprint

Padhye, A., Kang, K., Kong, F. Y., Sindoni, N., Yu, Q., 姜, 柏., Chang, W.-H., Coker, O., Kim, E., Dilly, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756013

Abstract 4228: Integrated drug high-throughput screening and quantitative phosphoproteomics rationalizes combination therapy for mutant KRAS pancreatic cancer

Capri, J. R., Le, T. D., Radu, C. G., & Donahue, T. R. (2019) · Molecular and Cellular Biology / Genetics · doi:10.1158/1538-7445.sabcs18-4228